Last reviewed · How we verify
Multi-Dose Antibiotic
A multi-dose antibiotic formulation that delivers multiple antimicrobial agents to treat bacterial infections.
A multi-dose antibiotic formulation that delivers multiple antimicrobial agents to treat bacterial infections. Used for Bacterial infections (specific indications unknown without product specification).
At a glance
| Generic name | Multi-Dose Antibiotic |
|---|---|
| Also known as | ARM 2: Multi-Dose Antibiotic Prophylaxis |
| Sponsor | The Cleveland Clinic |
| Drug class | Antibiotic combination |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is a marketed antibiotic product from Cleveland Clinic that combines multiple antibiotic agents in a single dosing regimen. The specific mechanism depends on the constituent antibiotics, which typically work by inhibiting bacterial cell wall synthesis, protein synthesis, or nucleic acid replication. Multi-dose formulations are designed to optimize pharmacokinetics and improve patient compliance.
Approved indications
- Bacterial infections (specific indications unknown)
Common side effects
- Gastrointestinal disturbance
- Hypersensitivity reaction
- Photosensitivity
Key clinical trials
- IO Vancomycin Spine (PHASE2, PHASE3)
- Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) (PHASE2)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation (PHASE2)
- Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multi-Dose Antibiotic CI brief — competitive landscape report
- Multi-Dose Antibiotic updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI